{"id":2433,"date":"2017-11-28T17:49:27","date_gmt":"2017-11-28T12:19:27","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2433"},"modified":"2021-07-24T12:56:53","modified_gmt":"2021-07-24T07:26:53","slug":"notizia-58","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-58","title":{"rendered":"Biohaven\u2019s trial ; GSK integrates; FDA Approval; Phase III trial"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69d493d3e2427\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69d493d3e2427\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-58\/#Biohaven_Completes_Enrollment_of_Rimegepant_in_Second_Pivotal_Phase_3_Clinical_Trial_for_the_treatment_of_Migraine\" >Biohaven Completes Enrollment of Rimegepant in Second Pivotal Phase 3 Clinical Trial for the treatment of Migraine<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-58\/#GSK_to_integrate_Owlstone_Medicals_Breath_Biopsy_Platform_into_their_Clinical_Trial\" >GSK to integrate Owlstone Medical\u2019s Breath Biopsy Platform into their Clinical Trial<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-58\/#Teligent_has_recently_got_the_First_FDA_Generic_Approval_of_Hydrocortisone_Butyrate_Lotion_01\" >Teligent has recently got the First FDA Generic Approval of Hydrocortisone Butyrate Lotion 0.1%<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-58\/#After_positive_results_of_new_phase_III_trial_results_Catalyst_is_back_with_Firdapse_for_FDA_approval\" >After positive results of new phase III trial results Catalyst is back with Firdapse for FDA approval<\/a><\/li><\/ul><\/nav><\/div>\n<h3><span class=\"ez-toc-section\" id=\"Biohaven_Completes_Enrollment_of_Rimegepant_in_Second_Pivotal_Phase_3_Clinical_Trial_for_the_treatment_of_Migraine\"><\/span><strong>Biohaven Completes Enrollment of Rimegepant in Second Pivotal Phase 3 Clinical Trial for the treatment of Migraine <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Biohaven Pharmaceutical<\/strong> has recently announced the completion of enrollment of their study <strong>BHV3000-302<\/strong> in Phase 3. The company is examining the safety and efficacy of <strong>Rimegepant <\/strong>for the treatment of Migraine.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"GSK_to_integrate_Owlstone_Medicals_Breath_Biopsy_Platform_into_their_Clinical_Trial\"><\/span>GSK to integrate Owlstone Medical\u2019s Breath Biopsy Platform into their Clinical Trial<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Owlstone Medical<\/strong> has announced that GSK will incorporate Owlstone Medical\u2019s Breath Biopsy platform into their clinical development programme of<strong> Danirixin.<\/strong>\u00a0It is a novel drug candidate in its respiratory disease pipeline.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Teligent_has_recently_got_the_First_FDA_Generic_Approval_of_Hydrocortisone_Butyrate_Lotion_01\"><\/span>Teligent has recently got the First FDA Generic Approval of Hydrocortisone Butyrate Lotion 0.1%<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Teligent<\/strong> a New Jersey-based specialty generic pharmaceutical company, has recently announced that it has received generic drug approval for the Company\u2019s abbreviated new drug application from the FDA of <strong>Hydrocortisone Butyrate Lotion 0.1%<\/strong> used for treating various skin related disorders.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"After_positive_results_of_new_phase_III_trial_results_Catalyst_is_back_with_Firdapse_for_FDA_approval\"><\/span>After positive results of new phase III trial results Catalyst is back with Firdapse for FDA approval<span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Catalyst Pharmaceuticals<\/strong> is back about <strong>18 months<\/strong> after the FDA filtered out their lead drug <strong>Firdapse <\/strong>(amifampridine phosphate) again to the clinic with a demand for more clinical data. The drug is used for the treatment of patients suffering from LEMS (<strong>Lambert Eaton Myasthenic Syndrome<\/strong>).<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biohaven Completes Enrollment of Rimegepant in Second Pivotal Phase 3 Clinical Trial for the treatment of Migraine Biohaven Pharmaceutical has recently announced the completion of enrollment of their study BHV3000-302 in Phase 3. The company is examining the safety and efficacy of Rimegepant for the treatment of Migraine. GSK to integrate Owlstone Medical\u2019s Breath Biopsy [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2434,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1195,1185,1155,1191,204,704,1188,1184,903,1190,1186,349,1187,1181,1193,730,1192,1182,639,706,1183,1194,1189],"industry":[17225],"therapeutic_areas":[17229,17237,17227,17234,17243],"class_list":["post-2433","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-biohaven","tag-catalyst-pharmaceuticals","tag-consultancy","tag-danirixin","tag-delveinsight","tag-fda","tag-firdapse","tag-google-news","tag-gsk","tag-hydrocortisone-butyrate-lotion-0-1","tag-lambert-eaton-myasthenic-syndrome","tag-latest-pharma-news","tag-lems","tag-market-consultant","tag-migraine","tag-notizia","tag-owlstone-medicals-breath-biopsy","tag-pharma-consultants","tag-pharma-news","tag-pharmaceutical-industry","tag-pharmaceutical-news","tag-rimegepant","tag-teligent","industry-pharmaceutical","therapeutic_areas-central-nervous-system","therapeutic_areas-dermatology","therapeutic_areas-immunological-and-autoimmune-disorders","therapeutic_areas-rare-diseases","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Rimegepant P-III trial; NDA to Teligent&#039;s drug; Catalyst&#039; s Firdapse;<\/title>\n<meta name=\"description\" content=\"Biohaven Pharmaceutical has recently announced the completion of enrollment of their study BHV3000-302 in Phase 3. The.....\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-58\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rimegepant P-III trial; NDA to Teligent&#039;s drug; Catalyst&#039; s Firdapse;\" \/>\n<meta property=\"og:description\" content=\"Biohaven Pharmaceutical has recently announced the completion of enrollment of their study BHV3000-302 in Phase 3. The.....\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-58\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-11-28T12:19:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2450\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Rimegepant P-III trial; NDA to Teligent's drug; Catalyst' s Firdapse;","description":"Biohaven Pharmaceutical has recently announced the completion of enrollment of their study BHV3000-302 in Phase 3. The.....","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-58","og_locale":"en_US","og_type":"article","og_title":"Rimegepant P-III trial; NDA to Teligent's drug; Catalyst' s Firdapse;","og_description":"Biohaven Pharmaceutical has recently announced the completion of enrollment of their study BHV3000-302 in Phase 3. The.....","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-58","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-11-28T12:19:27+00:00","article_modified_time":"2021-07-24T07:26:53+00:00","og_image":[{"width":2450,"height":1080,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-58","url":"https:\/\/www.delveinsight.com\/blog\/notizia-58","name":"Rimegepant P-III trial; NDA to Teligent's drug; Catalyst' s Firdapse;","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-58#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-58#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg","datePublished":"2017-11-28T12:19:27+00:00","dateModified":"2021-07-24T07:26:53+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Biohaven Pharmaceutical has recently announced the completion of enrollment of their study BHV3000-302 in Phase 3. The.....","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-58"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-58#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop.jpg","width":2450,"height":1080,"caption":"News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/11\/09021224\/News-Hero-Crop-300x132.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Biohaven<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Catalyst Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Danirixin<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Firdapse<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">google news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GSK<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hydrocortisone Butyrate Lotion 0.1%<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Lambert Eaton Myasthenic Syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">LEMS<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">market consultant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Migraine<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Owlstone Medical\u2019s Breath Biopsy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consultants<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharmaceutical news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Rimegepant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Teligent<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Biohaven<\/span>","<span class=\"advgb-post-tax-term\">Catalyst Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">consultancy<\/span>","<span class=\"advgb-post-tax-term\">Danirixin<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Firdapse<\/span>","<span class=\"advgb-post-tax-term\">google news<\/span>","<span class=\"advgb-post-tax-term\">GSK<\/span>","<span class=\"advgb-post-tax-term\">Hydrocortisone Butyrate Lotion 0.1%<\/span>","<span class=\"advgb-post-tax-term\">Lambert Eaton Myasthenic Syndrome<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">LEMS<\/span>","<span class=\"advgb-post-tax-term\">market consultant<\/span>","<span class=\"advgb-post-tax-term\">Migraine<\/span>","<span class=\"advgb-post-tax-term\">Notizia<\/span>","<span class=\"advgb-post-tax-term\">Owlstone Medical\u2019s Breath Biopsy<\/span>","<span class=\"advgb-post-tax-term\">pharma consultants<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/span>","<span class=\"advgb-post-tax-term\">pharmaceutical news<\/span>","<span class=\"advgb-post-tax-term\">Rimegepant<\/span>","<span class=\"advgb-post-tax-term\">Teligent<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Nov 28, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Nov 28, 2017 5:49 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2433","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2433"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2433\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2434"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2433"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2433"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2433"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2433"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2433"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}